IOLCP Q1 FY26 Concall Decoded: From Painkillers to Patents

1. Opening Hook

Remember when IOLCP was only “that Ibuprofen guy”? Well, Q1 FY26 proves the company’s finally tired of being typecast. Like Bollywood actors suddenly taking OTT web series roles, IOL is diversifying into Paracetamol, Metformin, Minoxidil (yep, hair-growth APIs) and even flaunting EU certifications. The vibe: from one-drug wonder to multi-API universe. Stick around—because this transcript had everything from Trump tariffs to baldness cures.

2. At a Glance

Revenue – ₹552 cr → Grew 9.8% YoY, a rare pharma/chem mix that didn’t look hungover.
EBITDA – ₹69.5 cr → Jumped 19.5% YoY; margin at 12.4%, proving cost control works better than most diets.
PAT – ₹34 cr → Up 14.4% YoY, steady as a monk.
Cash PAT – ₹55 cr → Grew 16% YoY; cash flows doing cardio.
Non-Ibuprofen APIs – 34% share → Moving towards the long-promised 50:50 split.
Exports – 25% today, target 40% → Slowly applying for “global supplier” passport.
Debt – Zero → Balance sheet cleaner than a Swachh Bharat poster.

3. Management’s Key Commentary

“Paracetamol demand is above pre-COVID, prices still low.”
Translation: No pandemic-style party, just a boring but steady family dinner.

“Our 10,800 MTPA para plant will hit 60% utilization by Q3.”
Translation: Plant finally moving from idle to Instagram-active.

“Non-Ibuprofen APIs can double to ₹900–1,000 cr in 2–3 years.”
Translation: Diversification finally has numbers, not just vibes.

“REACH registration for Acetic Anhydride opens EU doors.”
Translation: Can now charge Euros instead of rupees—better margins, same molecule.

“Ibuprofen exports: 70% to Europe/LATAM, none to US.”
Translation: Avoided Trump tariffs drama; staying out of MAGA’s medicine cabinet.

“Capex of ₹150–200 cr continues, with new 100-acre site coming.”
Translation: Growth optionality + landbank = pharma plus real estate twist.

“We will hit 14–15% EBITDA margins soon.”
Translation: 15% margin is IOLCP’s version of New Year resolution.

4. Numbers Decoded

Source table

Metric	Value (Q1 FY26)	YoY Change	One-Line Analysis
Revenue – The Topline	₹552 cr	+9.8%	APIs grew, chemicals sulked.
EBITDA – The Buffer	₹69.5 cr	+19.5%	Margins fattened on better mix.
EBITDA Margin – Diva	12.4%	+102 bps	Slowly inching to 15%, still flirting.
PAT – The Net Cake	₹34 cr	+14.4%	Solid, not flashy.
Cash PAT – The Muscle	₹55 cr	+16%	Cash flows healthier than earnings.
Non-Ibuprofen Share	34%	+500 bps	Diversification story finally visible.
Export Contribution	25%	+~300 bps	Marching to 40% target by FY28.

5. Analyst Questions

Paracetamol + Acetic Anhydride demand? → Prices bottomed, demand stable, plant utilization rising.
Middle

To Read Full 16 Point